{"product_id":"gallbladder-cancer-a-complete-guide-to-causes-risks-detection-and-treatment","title":"Gallbladder Cancer: A Complete Guide to Causes, Risks, Detection and Treatment","description":"\u003cp\u003eGallbladder cancer (GBC) is the most common cancer of the biliary tract (the system of ducts that carries bile from the liver and gallbladder to the intestine) and carries a very poor prognosis once it reaches an advanced stage. Because early disease rarely causes symptoms, most cases are found by accident after gallbladder removal for gallstones. Chronic, long-standing inflammation is the main driver of this cancer, whether or not gallstones are present, and researchers have now mapped two distinct pathways by which normal gallbladder tissue turns cancerous. Surgery remains the only treatment that can cure GBC, but few patients qualify for it, and standard chemotherapy and newer targeted and immune-based therapies offer limited benefit — which is why better screening tools, biomarkers and drug development are urgent priorities.\u003c\/p\u003e\n\n\u003ch1\u003eGallbladder Cancer: A Complete Guide to Causes, Risks, Detection and Treatment\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#overview\"\u003eOverview: What Is Gallbladder Cancer?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#background\"\u003eThe Gallbladder and the Biliary Tract\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#epidemiology\"\u003eHow Common Is Gallbladder Cancer?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#risk-factors\"\u003eWho Is at Risk?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mechanisms\"\u003eHow Gallbladder Cancer Develops: The Role of Inflammation\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#metaplasia\"\u003eThe Metaplasia–Dysplasia–Carcinoma Pathway\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#adenoma\"\u003eThe Adenoma–Carcinoma Pathway\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#diagnosis\"\u003eDiagnosis and Its Challenges\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eTreatment: Current Options and Their Limits\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications: What This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of Current Knowledge\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Actionable Advice\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eGallbladder cancer is the most common biliary tract cancer and is usually diagnosed late, often incidentally after gallbladder removal for gallstones.\u003c\/li\u003e\n\u003cli\u003eChronic inflammation is the main driver, with most cancers following a metaplasia–dysplasia–carcinoma sequence and 5–10% an adenoma–carcinoma sequence.\u003c\/li\u003e\n\u003cli\u003eGallstones are present in up to 90% of patients at diagnosis, but only about 1% of people with gallstones develop gallbladder cancer.\u003c\/li\u003e\n\u003cli\u003eSurgery is the only curative treatment, yet few cases qualify; most treatment given after surgery has a very low response rate, while targeted and immune therapies have emerged as promising alternatives to extend survival and quality of life.\u003c\/li\u003e\n\u003cli\u003eIn a mouse model, ezetimibe prevented gallstone formation and the onset of metaplasia and dysplasia, suggesting a possible chemoprevention strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"overview\"\u003eOverview: What Is Gallbladder Cancer?\u003c\/h2\u003e\n\n\u003cp\u003eGallbladder cancer (GBC) is the most common cancer of the biliary tract, the network of organs and ducts that produce and transport bile. It is also one of the most aggressive. The disease tends to be diagnosed late, when treatment options are few, and outcomes are poor at those advanced stages.\u003c\/p\u003e\n\n\u003cp\u003eEarly detection at a stage where surgery could cure the disease remains very difficult. Patients rarely notice symptoms early on. In fact, most gallbladder cancers are discovered incidentally — meaning they are found unexpectedly — when pathologists examine gallbladder tissue removed during a \u003cstrong\u003echolecystectomy\u003c\/strong\u003e (surgical removal of the gallbladder), usually performed because of symptomatic gallstones.\u003c\/p\u003e\n\n\u003cp\u003eLongstanding chronic inflammation is an important driver of this cancer, regardless of whether gallstones are present (lithiasic inflammation) or absent (non-lithiasic inflammation). New molecular technologies have given researchers a much deeper understanding of how inflammation triggers tumors and how these tumors progress.\u003c\/p\u003e\n\n\u003cp\u003eSurgical removal is the only treatment with curative intent for gallbladder cancer, but very few cases are suitable for this operation. Most adjuvant therapy (treatment given after surgery) produces a very low response rate. These unmet needs have driven efforts to find reliable biomarkers — measurable biological signals — for screening, therapy selection and prognosis.\u003c\/p\u003e\n\n\u003ch2 id=\"background\"\u003eThe Gallbladder and the Biliary Tract\u003c\/h2\u003e\n\n\u003cp\u003eThe gallbladder is a small, pear-shaped organ that sits on the undersurface of the liver. It stores and concentrates bile, a digestive fluid. Bile drains from the gallbladder through the \u003cstrong\u003ecystic duct\u003c\/strong\u003e, which joins the common hepatic duct to form the \u003cstrong\u003ecommon bile duct\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eAnatomically, the gallbladder wall is unusual. It has a discontinuous muscle layer and lacks a muscularis mucosa (a thin layer of muscle found in most of the digestive tract). About 30% of the gallbladder's surface is attached directly to the liver; the remaining surface is covered by peritoneum, the membrane that lines the abdominal cavity.\u003c\/p\u003e\n\n\u003cp\u003eBiliary tract cancers (BTC) include \u003cstrong\u003echolangiocarcinoma\u003c\/strong\u003e (cancer of the bile ducts, subdivided into intrahepatic, perihilar and extrahepatic types) and gallbladder cancer. When a tumor arises at the neck of the gallbladder, it can look identical to a hilar or mid-common-bile-duct cholangiocarcinoma, making the two difficult to tell apart. However, gallbladder cancer is more aggressive, and patient outcomes are often poorer than for perihilar cholangiocarcinoma.\u003c\/p\u003e\n\n\u003cp\u003eAbout 95% of gallbladder cancers arise from epithelial cells (the cells lining body surfaces) with features of cholangiocytes, the cells that line the bile ducts. The most common histological type (the type identified under a microscope) is \u003cstrong\u003eadenocarcinoma\u003c\/strong\u003e, which accounts for more than 90% of cases. Less common subtypes include squamous, undifferentiated, mucinous and neuroendocrine carcinomas.\u003c\/p\u003e\n\n\u003ch2 id=\"epidemiology\"\u003eHow Common Is Gallbladder Cancer?\u003c\/h2\u003e\n\n\u003cp\u003eIn 2020, an estimated 115,949 new cases of gallbladder cancer were diagnosed worldwide. This ranked the disease 25th out of 36 cancers tracked across 185 countries.\u003c\/p\u003e\n\n\u003cp\u003eGlobally, gallbladder cancer is more common in women than in men. In the Americas, the incidence rate ratio between women and men is about 2 to 1. In the United States, the age-adjusted incidence rate is 1.9 per 100,000 women compared with 1.1 per 100,000 men — roughly 1.9 in every 100,000 women and 1.1 in every 100,000 men. In Chile, the rates are much higher: they range from 8.3 to 18.8 per 100,000 women compared with 3.2 to 5.8 per 100,000 men.\u003c\/p\u003e\n\n\u003cp\u003eRisk increases with age. In Delhi, India, the age-adjusted incidence rate climbs from less than 1 per 100,000 in people under 30 years of age to a peak of 43.7 per 100,000 in women and 24.0 per 100,000 in men aged 70–74 years. The average age at diagnosis is about 20 years younger in India than in Western countries.\u003c\/p\u003e\n\n\u003cp\u003eRegions with a higher human development index, higher income, higher tobacco use, higher rates of overweight or obesity, and higher prevalence of hypercholesterolemia (high blood cholesterol) tend to have higher gallbladder cancer incidence and mortality.\u003c\/p\u003e\n\n\u003ch3\u003eGlobal Trends Over Time\u003c\/h3\u003e\n\n\u003cp\u003eBetween 1980 and 2017, gallbladder cancer incidence fell in men in 3 of 45 countries (7%) and rose in 5 of 45 countries (11%). In women, incidence fell in 13 of 45 countries (29%) and rose in 4 of 45 countries (9%).\u003c\/p\u003e\n\n\u003cp\u003eMortality (death rates) declined in a larger share of countries. Deaths fell among men in 8 of 44 countries (18%) and among women in 18 of 44 countries (41%).\u003c\/p\u003e\n\n\u003cp\u003eThese averages hide important differences between populations. In the United States, incidence increased among Black individuals and among people under 45 years of age — both by 1.8% per year — from 1999 to 2003. Between 1980 and 2017, mortality rose among men in Ecuador (2.3% per year) and Germany (1.2% per year), and among women in the Netherlands (2.9% per year) and the United Kingdom (2.6% per year). Mortality also appears to have increased in Colombian and Canadian men between 2010 and 2016.\u003c\/p\u003e\n\n\u003ch3\u003eGeographic Hotspots\u003c\/h3\u003e\n\n\u003cp\u003eAlthough gallbladder cancer is rare in most countries, its distribution around the world is remarkably uneven. Nearly 40% of the countries with the highest incidence rates — 15 of the 38 countries with rates of at least 1.3 per 100,000 — are in South America, South Asia and Southeast Asia. Indigenous populations in South America, Northern India and East Asia have particularly high rates.\u003c\/p\u003e\n\n\u003cp\u003eIn the United States, the highest rates occur among Native American, Hispanic and other non-white populations. The proportion of biliary tract cancers caused by gallbladder cancer is higher among American Native and Alaskan Native individuals than in any other population. This disparity varies by region: Alaskan Native and American Native individuals in the Southwest have the highest incidence compared with non-Hispanic White individuals.\u003c\/p\u003e\n\n\u003cp\u003eIndia illustrates the geographic variation vividly. About 10% of the world's gallbladder cancers are estimated to occur there. In Delhi, in the north, the incidence is nearly ten times higher than in Chennai, in the south. Even after migrating to a low-risk region, people born in a high-risk region of India had a slightly increased risk compared with those born in a low-risk region (odds ratio 1.4, 95% confidence interval 1.0–1.8). In Chile, age-standardized incidence rates are about two to three times higher in south-central Chile than in the north. Environmental factors, along with population-specific risk factors, may explain these patterns.\u003c\/p\u003e\n\n\u003ch2 id=\"risk-factors\"\u003eWho Is at Risk?\u003c\/h2\u003e\n\n\u003cp\u003eNative American individuals carry a disproportionately high burden of both gallbladder cancer and gallstones, a major risk factor for the cancer. Gallstones are present at diagnosis in up to 90% of patients with gallbladder cancer, especially in high-risk areas and populations. Gallstones are strongly associated with increased gallbladder cancer risk and are typically diagnosed years before the cancer develops.\u003c\/p\u003e\n\n\u003cp\u003ePopulations with high gallbladder cancer incidence tend to have high gallstone prevalence, although the link is weaker than you might expect. For example, in several East Asian countries, gallbladder cancer incidence is elevated even though gallstone disease is uncommon. This pattern suggests a cause unrelated to gallstones in those countries, such as \u003cstrong\u003epancreatobiliary maljunction\u003c\/strong\u003e (a congenital abnormality where the pancreatic and bile ducts join outside the intestinal wall).\u003c\/p\u003e\n\n\u003cp\u003eEnvironmental exposures also vary by region. Mustard oil, used mainly in the high-risk region of northern India and in Nepal, has been associated with gallbladder cancer.\u003c\/p\u003e\n\n\u003ch3\u003eDo Gallstones Actually Cause Gallbladder Cancer?\u003c\/h3\u003e\n\n\u003cp\u003eSome researchers have questioned whether gallstones truly cause gallbladder cancer, since the two conditions share many risk factors. But a technique called \u003cstrong\u003eMendelian randomization\u003c\/strong\u003e — which uses genetic variants to test whether an exposure causally affects an outcome — supports a causal role.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eOne study found an odds ratio of 2.0 (95% CI 1.4–2.8) for gallstones and gallbladder cancer in Chile, and 5.0 (95% CI 2.2–11.3) in Europe.\u003c\/li\u003e\n  \u003cli\u003eAnother study found an odds ratio of 4.5 (95% CI 3.5–5.8) for self-reported gallstones and 2.0 (95% CI 1.5–2.7) for objectively diagnosed gallstones in India.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAn odds ratio above 1.0 means the exposure is linked to higher risk; for example, an odds ratio of 2.0 means roughly double the odds.\u003c\/p\u003e\n\n\u003cp\u003eA transcriptomic analysis (a study of which genes are switched on or off) examined 10 patients with gallbladder cancer and 30 patients with gallstones. The gallstone group was divided into three subgroups of 10 patients each, based on how long it had been since their gallstone diagnosis: 1–3 years, 5–10 years, or more than 10 years before surgery. Patients whose gallstones had been diagnosed only 1–3 years earlier had the fewest number of differentially expressed genes in gallbladder tissue compared with cancer tissue — meaning their tissue looked most similar to cancer tissue. The authors suggest that worsening symptoms shortly after a gallstone diagnosis might signal an increased risk of gallbladder cancer. Patients diagnosed more than 10 years before cholecystectomy showed the next highest similarity, supporting a role for chronic trauma and inflammation in gallstone-related cancer development.\u003c\/p\u003e\n\n\u003ch3\u003eOther Contributing Factors\u003c\/h3\u003e\n\n\u003cp\u003eDespite the evidence for causality, only about 1% of people with gallstones develop gallbladder cancer — about 1 in 100. This strongly suggests that additional factors are involved. Genetics may play a part: a genome-wide association study in an Indian population identified three germline variants (inherited gene changes) in the ABCB1 and ABCB4 genes that were later also found in Chilean and European populations.\u003c\/p\u003e\n\n\u003cp\u003eExposure to \u003cstrong\u003eaflatoxin B1\u003c\/strong\u003e, a potent liver carcinogen produced by certain molds, has also been linked to gallbladder cancer. Studies found odds ratios of 2.7 (95% CI 1.7–4.3) in China and 9.4 (95% CI 2.8–37.2) in Chile when comparing people with gallbladder cancer to those with gallstones but no cancer. Some parts of the United States, including the Southwest, have climates that make crops prone to contamination with \u003cem\u003eAspergillus flavus\u003c\/em\u003e, a mold that is a primary producer of aflatoxin B1.\u003c\/p\u003e\n\n\u003cp\u003eAflatoxin exposure also appears to be high in areas of Nepal near the high-risk region of northern India, which may contribute to elevated rates in these Asian populations. Marginalized populations have higher aflatoxin exposure, potentially because they consume more non-commercially produced food. High aflatoxin exposure has been documented in indigenous and low-socioeconomic-status populations in Mexico and Africa, raising the question of whether aflatoxin might increase gallbladder cancer risk in indigenous populations in the United States and elsewhere.\u003c\/p\u003e\n\n\u003cp\u003eAdditional reported risk factors include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePolypoid gallbladder lesions (growths projecting into the gallbladder)\u003c\/li\u003e\n  \u003cli\u003eMetabolic syndrome\u003c\/li\u003e\n  \u003cli\u003eParity (number of pregnancies)\u003c\/li\u003e\n  \u003cli\u003eBile duct abnormalities\u003c\/li\u003e\n  \u003cli\u003ePrimary sclerosing cholangitis (a chronic liver and bile duct disease)\u003c\/li\u003e\n  \u003cli\u003eFamily history of gallstones\u003c\/li\u003e\n  \u003cli\u003e\n\u003cem\u003eSalmonella enterica\u003c\/em\u003e serovar Typhi infection (the bacterium that causes typhoid fever)\u003c\/li\u003e\n  \u003cli\u003eExposure to heavy metals\u003c\/li\u003e\n  \u003cli\u003eDiet\u003c\/li\u003e\n  \u003cli\u003eChemical exposures such as organochlorines (a class of industrial chemicals and pesticides)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"mechanisms\"\u003eHow Gallbladder Cancer Develops: The Role of Inflammation\u003c\/h2\u003e\n\n\u003cp\u003eChronic inflammation is the main process driving gallbladder cancer. Inflammation creates a permissive environment — one that allows and encourages malignant transformation and tumor progression.\u003c\/p\u003e\n\n\u003cp\u003eCurrent understanding recognizes two major histogenic pathways (routes by which normal tissue becomes cancer), both driven by long-standing inflammation, whether gallstones are present or not.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003eMost gallbladder cancers appear to develop when gallstones are present, following a \u003cstrong\u003emetaplasia–dysplasia–carcinoma sequence\u003c\/strong\u003e. Here, the gallbladder lining undergoes progressive changes under chronic inflammation, leading to carcinoma in situ (cancer confined to the surface layer) and finally invasive adenocarcinoma.\u003c\/li\u003e\n  \u003cli\u003eAbout 5–10% of gallbladder cancers appear to develop through an \u003cstrong\u003eadenoma–carcinoma sequence\u003c\/strong\u003e, which is less often linked to gallstones but still involves chronic inflammation that favors adenoma (a benign growth) formation and the buildup of molecular changes.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eBoth models are supported by morphological (structural) and molecular evidence, though understanding of the underlying mechanisms remains limited. Recent next-generation sequencing (NGS) and multi-omics studies — technologies that read large amounts of genetic and molecular data at once — have revealed key cancer-driving mutations, subtypes based on the tumor microenvironment, and important oncogenic (cancer-promoting) pathways.\u003c\/p\u003e\n\n\u003ch2 id=\"metaplasia\"\u003eThe Metaplasia–Dysplasia–Carcinoma Pathway\u003c\/h2\u003e\n\n\u003cp\u003eMost gallbladder cancers — 70–90% — arise in the setting of cholelithiasis (gallstones), which is considered the major risk factor. Gallstones, most of which consist mainly of cholesterol, form when environmental and genetic factors disrupt critical metabolic processes, producing gallbladder hypomotility (poor emptying) and altered bile acid composition.\u003c\/p\u003e\n\n\u003cp\u003eSpecifically, decreased bile acid production and increased secretion of hepatic and intestinal cholesterol into the bile result in cholesterol-supersaturated bile. This favors the precipitation of solid cholesterol crystals and gallstone formation.\u003c\/p\u003e\n\n\u003cp\u003eCholelithiasis is often asymptomatic, but about a quarter of cases — roughly 1 in 4 — can produce symptoms over decades through repeated acute episodes. These episodes involve total or partial blockage of the cystic duct and massive inflammatory destruction of the gallbladder lining. Continuous cycles of mucosal damage and repair, combined with the chemical pro-inflammatory effect of lithogenic (stone-forming) bile, create a long-standing chronic inflammatory response that disrupts cellular homeostasis (the cell's stable internal balance).\u003c\/p\u003e\n\n\u003cp\u003eThis chronic condition, called chronic cholecystitis (persistent gallbladder inflammation), is characterized by overexpression of \u003cstrong\u003ecyclooxygenase-2 (COX-2)\u003c\/strong\u003e, an enzyme involved in inflammation, and high infiltration of immune cells. These include T cells, B cells, COX-2\/iNOS-positive macrophages, iNOS-positive granulocytes and mast cells. Histological changes such as metaplasia (one cell type changing into another) and dysplasia (abnormal, precancerous cell growth) — both considered precursor lesions of gallbladder cancer — are common in this setting.\u003c\/p\u003e\n\n\u003ch3\u003eWhat Studies in Animals Show\u003c\/h3\u003e\n\n\u003cp\u003eStudies using mouse models of cholelithiasis have linked chronic cholecystitis with the histological and structural changes seen in the gallbladder lining. A new mouse model of gallbladder preneoplasia (precancerous change) showed that metaplasia and dysplasia are strongly associated with gallstone-mediated inflammation.\u003c\/p\u003e\n\n\u003cp\u003eThe timing of immune cell infiltration mattered. High infiltration of \u003cstrong\u003epolymorphonuclear neutrophils (PMN)\u003c\/strong\u003e and F4\/80+ macrophages early on correlated with hyperplasia (overgrowth of cells) and metaplasia. In contrast, increased infiltration of adaptive immune cells (CD4+ and CD8+ T cells) correlated with the development of dysplasia.\u003c\/p\u003e\n\n\u003cp\u003eNotably, inhibiting gallstone formation with ezetimibe, a cholesterol-lowering drug, prevented the excessive inflammatory response and the onset of metaplasia and dysplasia. This provides preclinical evidence for targeting gallstones as a chemoprevention strategy — using medication to prevent cancer — in high-risk populations.\u003c\/p\u003e\n\n\u003ch3\u003eGenetic Damage Accumulates Step by Step\u003c\/h3\u003e\n\n\u003cp\u003eSequential histological changes are accompanied by cumulative molecular alterations, which appear even in histologically normal gallbladder epithelia from patients with chronic cholecystitis. NGS-based mutational profiling showed that about 30% of chronic cholecystitis samples — 7 of 23 — had cancer-driver somatic alterations (mutations or copy loss) in the genes TP53, CDKN2A, PIK3R2 and CHD1.\u003c\/p\u003e\n\n\u003cp\u003eChronic inflammation is known to damage DNA through oxidative stress generated by elevated levels of \u003cstrong\u003ereactive oxygen species (ROS)\u003c\/strong\u003e and \u003cstrong\u003ereactive nitrogen species (RNS)\u003c\/strong\u003e — unstable molecules that harm cells. DNA damage activates various response pathways, including the p53-mediated tumor suppression pathway. This pathway acts as a major barrier against tumor formation by controlling processes such as apoptosis (programmed cell death), senescence (cellular aging) and cell-cycle arrest in damaged cells.\u003c\/p\u003e\n\n\u003cp\u003eSustained inflammation-related DNA damage may cause genomic instability and early p53 dysfunction. That dysfunction, in turn, enhances chronic inflammation and hyperactivates inflammatory mediators and pro-oncogenic signaling pathways, ultimately leading to neoplastic transformation of inflamed tissues.\u003c\/p\u003e\n\n\u003cp\u003eIn gallbladder carcinogenesis, \u003cstrong\u003eTP53 alterations are the earliest genetic events\u003c\/strong\u003e. They are detectable in chronic cholecystitis and accumulate as precursor lesions progress from metaplasia to invasive cancer. Loss of p53 function contributes similarly to many other inflammation-related cancers, including intestinal-type \u003cem\u003eHelicobacter pylori\u003c\/em\u003e-associated gastric adenocarcinoma (stomach cancer), fluke-related cholangiocarcinoma and ulcerative colitis-associated colorectal cancer.\u003c\/p\u003e\n\n\u003cp\u003eMore broadly, genetic abnormalities affecting DNA repair pathways appear to be frequent in gallbladder cancer. These include somatic mutations in direct DNA repair genes (predominantly ATM and BRCA2) and caretaker genes (predominantly TP53). Inefficient DNA repair leads to genome instability and the accumulation of mutations — a critical driver of cancer initiation and progression.\u003c\/p\u003e\n\n\u003cp\u003eAccordingly, \u003cstrong\u003eloss of heterozygosity (LOH)\u003c\/strong\u003e — the loss of one copy of a gene — is detected in chronic cholecystitis and progressively accumulates through the histogenic sequence. Tumor suppressor genes (genes that normally restrain cancer) affected by allelic loss include FHIT, APC, CDKN2A, CDH1, RB1, TP53 and DCC.\u003c\/p\u003e\n\n\u003cp\u003eThe expression of many of these genes is regulated by epigenetic mechanisms (changes that affect gene activity without altering the DNA sequence), particularly hypermethylation of their promoter regions — a chemical \"switch\" that silences genes. The number and magnitude of epigenetic alterations increase during gallbladder carcinogenesis and affect genes involved in communication between cells and their environment.\u003c\/p\u003e\n\n\u003ch3\u003eInflammation Recruited by the Tumor Itself\u003c\/h3\u003e\n\n\u003cp\u003eOnce a tumor is established, tumor cells can recruit inflammatory immune cells into their local microenvironment. Crosstalk between tumor and stromal cells (the supportive tissue around a tumor) then drives invasion and metastasis (spread to other parts of the body).\u003c\/p\u003e\n\n\u003cp\u003eThis cancer-elicited inflammation differs from the earlier pro-tumorigenic inflammation, but it results in a profoundly immunosuppressive microenvironment — a setting where the immune system is held back from attacking the tumor. The molecular mechanisms underlying these two inflammatory conditions, and their effect on gallbladder cancer, are only beginning to be clarified.\u003c\/p\u003e\n\n\u003ch2 id=\"adenoma\"\u003eThe Adenoma–Carcinoma Pathway\u003c\/h2\u003e\n\n\u003cp\u003eGallbladder cancer can also develop from adenomatous precursor lesions — growths that are not yet cancer — most of which occur in the context of non-lithiasic inflammation (inflammation without gallstones). This pathway accounts for 5–10% of gallbladder cancers and remains poorly characterized compared with the stepwise metaplasia–dysplasia–carcinoma model.\u003c\/p\u003e\n\n\u003cp\u003eThe 2019 World Health Organization (WHO) classification of tumors of the digestive system recognized the \u003cstrong\u003eintracholecystic papillary-tubular neoplasm (ICPN)\u003c\/strong\u003e as one of the precursor lesions of gallbladder carcinoma. An ICPN is an exophytic preinvasive neoplasm — a growth that projects outward from the mucosa into the gallbladder cavity rather than spreading within the wall.\u003c\/p\u003e\n\n\u003cp\u003eUnlike the flat premalignant lesions seen in cancers that arise via metaplasia–dysplasia, ICPNs are infrequently associated with cholelithiasis. However, they occur at a relatively high frequency — about 30% — in people with \u003cstrong\u003epancreaticobiliary maljunction (PBM)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003ePBM is a congenital malformation in which the junction of the pancreatic and bile ducts lies outside the duodenal wall. This condition causes bile stasis (poor bile flow) and chronic reflux of pancreatic juice into the biliary tract and gallbladder. There, activated proteolytic pancreatic enzymes modify bile composition and generate strong cytotoxic substances (such as lysolecithin) that damage the gallbladder lining and trigger a constant, excessive inflammatory state.\u003c\/p\u003e\n\n\u003cp\u003eThis process promotes oxidative stress and DNA damage. Evidence of this damage comes from the overexpression of 8-hydroxy-2'-deoxyguanosine and γ-H2AX (a biomarker for DNA double-strand breaks) in the gallbladder lining of patients with PBM. Together, these events may facilitate the formation of adenomatous lesions and their eventual malignant transformation into invasive carcinoma.\u003c\/p\u003e\n\n\u003ch3\u003eGenetic Changes in PBM-Related Gallbladder Cancer\u003c\/h3\u003e\n\n\u003cp\u003eGenetic changes underlying cancer development in patients with PBM-related gallbladder cancer include high frequencies of mutations in several genes:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eTP53 — 50%\u003c\/li\u003e\n  \u003cli\u003eEGFR — 20.6%\u003c\/li\u003e\n  \u003cli\u003eRB1 — 17.6%\u003c\/li\u003e\n  \u003cli\u003eERBB2 — 17.6%\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, the molecular pathology of ICPN lesions has not been studied extensively. To date, only one study has evaluated the mutational profile of ICPNs, in a total of 7 patients, 4 of whom had an associated invasive carcinoma. That study showed ICPNs are genetically distinct from gallbladder cancers that arise through the metaplasia–dysplasia–carcinoma sequence.\u003c\/p\u003e\n\n\u003cp\u003eSomatic mutations in STK11, CTNNB1 and APC were frequent — 43%, 29% and 14%, respectively — and were proposed as major driver genes for ICPNs. Genomic alterations in these genes have also been reported in advanced gallbladder cancer, suggesting that some of those tumors arose following an adenoma–carcinoma sequence. Identifying the molecular determinants that drive this pathway remains an open research question.\u003c\/p\u003e\n\n\u003ch2 id=\"diagnosis\"\u003eDiagnosis and Its Challenges\u003c\/h2\u003e\n\n\u003cp\u003eScreening and early diagnosis remain major challenges because patients rarely have specific symptoms. Most lesions are flat and arise against a background of chronic inflammation and gallbladder wall thickening caused by gallstones. This makes both clinical and imaging diagnosis difficult.\u003c\/p\u003e\n\n\u003cp\u003eThe consequences are significant. Without reliable early warning signs, most tumors are detected only after they have advanced — or incidentally, when a gallbladder is removed for other reasons. Standardizing the nomenclature (naming system) for preneoplastic and neoplastic lesions, along with surgical specimen processing and sampling, now provides reproducible and comparable research data. This standardization forms a basis for identifying and implementing early detection strategies and improving drug discovery.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eTreatment: Current Options and Their Limits\u003c\/h2\u003e\n\n\u003cp\u003eSurgical resection (removal of the tumor and surrounding tissue) is the only treatment with curative intent for gallbladder cancer. The central problem is that very few cases are suitable for resection.\u003c\/p\u003e\n\n\u003cp\u003eAdvanced gallbladder cancer is usually resistant to conventional cytotoxic therapy (chemotherapy that kills cancer cells). Drugs commonly used include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eGemcitabine\u003c\/li\u003e\n  \u003cli\u003eCisplatin\u003c\/li\u003e\n  \u003cli\u003e5-fluorouracil (5-FU)\u003c\/li\u003e\n  \u003cli\u003eOxaliplatin\u003c\/li\u003e\n  \u003cli\u003eCapecitabine\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMost adjuvant therapy after surgery has a very low response rate. Targeted therapy and immunotherapy (treatments that attack specific molecular targets or help the immune system fight cancer) have emerged as promising alternatives to extend survival and quality of life.\u003c\/p\u003e\n\n\u003cp\u003eAdvances in next-generation sequencing, multidisciplinary care, neoadjuvant strategies (treatment given before surgery), adjuvant strategies (treatment given after surgery) and novel systemic therapies — including chemotherapy and immunotherapies — are gradually changing the treatment paradigm and prognosis for this stubbornly difficult cancer.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications: What This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis research has several practical implications for people living with or at risk of gallbladder cancer.\u003c\/p\u003e\n\n\u003cp\u003eFirst, early detection is the single most important factor in survival. Because symptoms are rare, patients who fall into high-risk groups — particularly those with long-standing gallstones, PBM or a family history of biliary disease — should discuss screening approaches with their doctors.\u003c\/p\u003e\n\n\u003cp\u003eSecond, not all gallbladder inflammation carries the same risk. The research shows that gallstones diagnosed shortly before worsening symptoms (within 1–3 years) may signal elevated risk, and that inflammation lasting more than 10 years also increases risk through chronic damage.\u003c\/p\u003e\n\n\u003cp\u003eThird, the molecular discoveries open the door to personalized treatment. Identifying mutations in genes like TP53, EGFR, ERBB2, RB1, STK11, CTNNB1 and APC could one day guide which targeted therapies a patient receives.\u003c\/p\u003e\n\n\u003cp\u003eFourth, chemoprevention may become possible in high-risk populations. The mouse-model finding that ezetimibe prevented metaplasia and dysplasia by blocking gallstone formation is a proof of concept that deserves further study.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of Current Knowledge\u003c\/h2\u003e\n\n\u003cp\u003eThe authors are candid about what remains unknown. Several key limitations stand out.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstanding of mechanisms is still limited.\u003c\/strong\u003e Although both carcinogenic models (metaplasia–dysplasia–carcinoma and adenoma–carcinoma) are supported by morphological and molecular evidence, the underlying mechanisms are not fully worked out.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdenoma–carcinoma pathway is poorly characterized.\u003c\/strong\u003e Because it accounts for only 5–10% of cases, it has been studied far less than the more common pathway. Only one study has profiled ICPN mutations, and it included just 7 patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOnly about 1% of people with gallstones develop cancer\u003c\/strong\u003e — about 1 in 100 — so additional contributing factors, including genetic susceptibility, remain to be identified.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe link between gallstones and cancer is controversial.\u003c\/strong\u003e Because the two conditions share many risk factors, some researchers question whether gallstones are truly causal; however, Mendelian randomization studies support causality.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGeographic correlation is imperfect.\u003c\/strong\u003e In several East Asian countries, gallbladder cancer incidence is high while gallstone prevalence is low, suggesting other causes such as pancreatobiliary maljunction may be at work.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe relationship between the two types of inflammation\u003c\/strong\u003e — the inflammation that initiates tumors and the inflammation that tumors themselves recruit — is only beginning to be clarified.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Actionable Advice\u003c\/h2\u003e\n\n\u003cp\u003eSeveral unmet clinical needs must be addressed to improve gallbladder cancer management: discovering and validating reliable biomarkers for screening, therapy selection and prognosis. Until then, the following practical steps may help patients:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your risk profile.\u003c\/strong\u003e Gallstones, especially long-standing ones, are the strongest known risk factor. If you have gallstones, particularly with worsening symptoms, discuss your risk with a physician.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReport changing symptoms promptly.\u003c\/strong\u003e Because tissue from patients whose gallstones were diagnosed within the past 1–3 years most closely resembled cancer tissue, new or worsening symptoms after a recent gallstone diagnosis deserve attention.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about standardized pathology review.\u003c\/strong\u003e Standardized processing and sampling of gallbladder specimens improves the reliability of diagnosis and is now recommended.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSeek multidisciplinary care.\u003c\/strong\u003e Advances in multidisciplinary management, next-generation sequencing and novel systemic therapies are gradually improving outcomes, and access to specialists matters.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider biomarker testing for advanced disease.\u003c\/strong\u003e Molecular profiling may reveal actionable mutations that guide targeted therapy or immunotherapy choices.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss geographic and environmental exposures.\u003c\/strong\u003e In high-risk regions, exposure to aflatoxin B1, mustard oil and other environmental factors may be relevant, and food safety measures may reduce risk.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003ePatients should remember that this remains a difficult cancer with limited options — but the pace of discovery, especially in genomics and immunotherapy, is changing the outlook.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is gallbladder cancer?\u003c\/h3\u003e\n\u003cp\u003eGallbladder cancer is the most common cancer of the biliary tract, the network of organs and ducts that produce and transport bile. It is aggressive and usually diagnosed late, when treatment options are few. Most cases are found incidentally when a gallbladder is removed for gallstones. About 95% arise from epithelial cells, and more than 90% are adenocarcinomas.\u003c\/p\u003e\n\u003ch3\u003eWho is at risk for gallbladder cancer?\u003c\/h3\u003e\n\u003cp\u003eRisk is higher in women, older adults, and certain populations, including Native American, Hispanic, and indigenous groups in South America, Northern India, and East Asia. Gallstones are present in up to 90% of patients at diagnosis. Other reported risks include metabolic syndrome, bile duct abnormalities, primary sclerosing cholangitis, family history of gallstones, Salmonella Typhi infection, and aflatoxin B1 exposure.\u003c\/p\u003e\n\u003ch3\u003eDo gallstones cause gallbladder cancer?\u003c\/h3\u003e\n\u003cp\u003eGallstones are strongly associated with gallbladder cancer, and Mendelian randomization studies support a causal role. For example, one study found an odds ratio of 2.0 in Chile and 5.0 in Europe. However, only about 1% of people with gallstones develop gallbladder cancer, so other factors such as genetics and environmental exposures are also involved.\u003c\/p\u003e\n\u003ch3\u003eWhat are the symptoms of gallbladder cancer?\u003c\/h3\u003e\n\u003cp\u003eEarly gallbladder cancer rarely causes symptoms, which is why most cases are found incidentally after gallbladder removal for gallstones. When symptoms do occur, they may include worsening symptoms shortly after a gallstone diagnosis. The text notes that patients whose gallstones were diagnosed 1–3 years before surgery had tissue that most closely resembled cancer tissue, suggesting new or worsening symptoms deserve attention.\u003c\/p\u003e\n\u003ch3\u003eHow is gallbladder cancer treated?\u003c\/h3\u003e\n\u003cp\u003eSurgery is the only treatment with curative intent, but few cases are suitable for resection. Advanced disease is usually resistant to conventional chemotherapy. Drugs commonly used include gemcitabine, cisplatin, 5-fluorouracil, oxaliplatin, and capecitabine. Targeted therapy and immunotherapy are emerging options to extend survival and quality of life. Most adjuvant therapy after surgery has a very low response rate.\u003c\/p\u003e\n\u003ch3\u003eWhat does it mean if I have gallstones and worsening symptoms?\u003c\/h3\u003e\n\u003cp\u003eA transcriptomic analysis of 10 gallbladder cancer patients and 30 gallstone patients found that those whose gallstones were diagnosed 1–3 years before surgery had tissue that most closely resembled cancer tissue. The authors suggest that worsening symptoms shortly after a gallstone diagnosis might signal an increased risk of gallbladder cancer. Discuss any new or worsening symptoms with your doctor promptly.\u003c\/p\u003e\n\u003ch3\u003eCan gallbladder cancer be prevented?\u003c\/h3\u003e\n\u003cp\u003eThere is no proven prevention, but a mouse model of gallbladder preneoplasia showed that inhibiting gallstone formation with ezetimibe prevented excessive inflammation and the onset of metaplasia and dysplasia. This provides preclinical evidence for targeting gallstones as a chemoprevention strategy in high-risk populations. Food safety measures may reduce aflatoxin exposure in high-risk regions. Discuss risk reduction with your doctor.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with gallbladder cancer or a gallbladder mass found after gallbladder removal seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth seeking when gallbladder cancer is diagnosed incidentally after cholecystectomy, because most cases are found this way and surgical removal is the only treatment with curative intent, yet few cases are suitable for resection. Standardized pathology review of gallbladder specimens improves diagnostic reliability, and molecular profiling may reveal mutations in genes such as TP53, EGFR, ERBB2, RB1, STK11, CTNNB1 and APC that could guide targeted therapy or immunotherapy choices. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Gallbladder cancer - review\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Juan C. Roa, Patricia García, Vinay K. Kapoor, Shishir K. Maithel, Milind Javle, Jill Koshiol\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Department of Pathology, Millennium Institute on Immunology and Immunotherapy, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; Department of Hepato-pancreato-biliary (HPB) Surgery, Mahatma Gandhi Medical College \u0026amp; Hospital (MGMCH), Jaipur, Rajasthan, India; Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA; Department of Gastrointestinal Medical Oncology, UT M.D. Anderson Cancer Center, Houston, Texas, USA; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e \u003cem\u003eNature Reviews Disease Primers\u003c\/em\u003e, volume 8, article 69 (2022). DOI: 10.1038\/s41572-022-00398-y. Available via HHS Public Access (PubMed Central), author manuscript.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47738960412828,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/ar\/products\/gallbladder-cancer-a-complete-guide-to-causes-risks-detection-and-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}